sch 58261 has been researched along with tozadenant in 3 studies
| Studies (sch 58261) | Trials (sch 58261) | Recent Studies (post-2010) (sch 58261) | Studies (tozadenant) | Trials (tozadenant) | Recent Studies (post-2010) (tozadenant) |
|---|---|---|---|---|---|
| 46 | 0 | 14 | 18 | 1 | 16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| de Lera Ruiz, M; Lim, YH; Zheng, J | 1 |
| Gaba, S; Gupta, GD; Monga, V; Patel, R; Saini, A; Singh, G | 1 |
| Bai, R; Cai, H; Ge, J; He, X; Xie, T; Yao, C; Ye, XY; Zhong, Z; Zhu, J | 1 |
3 review(s) available for sch 58261 and tozadenant
| Article | Year |
|---|---|
Adenosine A2A receptor as a drug discovery target.
Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Crystallography, X-Ray; Drug Discovery; Humans; Ligands; Protein Conformation; Receptor, Adenosine A2A; Signal Transduction | 2014 |
Adenosine receptor antagonists: Recent advances and therapeutic perspective.
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Structure-Activity Relationship | 2022 |
Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.
Topics: Biological Products; Blood-Brain Barrier; Dopaminergic Neurons; Humans; Neurodegenerative Diseases; Parkinson Disease | 2022 |